114 related articles for article (PubMed ID: 16700331)
1. Engineered cell therapy for sustained local myocardial delivery of nonsecreted proteins.
Bian J; Kiedrowski M; Mal N; Forudi F; Penn MS
Cell Transplant; 2006; 15(1):67-74. PubMed ID: 16700331
[TBL] [Abstract][Full Text] [Related]
2. Effect of cell-based intercellular delivery of transcription factor GATA4 on ischemic cardiomyopathy.
Bian J; Popovic ZB; Benejam C; Kiedrowski M; Rodriguez LL; Penn MS
Circ Res; 2007 Jun; 100(11):1626-33. PubMed ID: 17495229
[TBL] [Abstract][Full Text] [Related]
3. The study of the intercellular trafficking of the fusion proteins of herpes simplex virus protein VP22.
Xue X; Huang J; Wang H
PLoS One; 2014; 9(6):e100840. PubMed ID: 24955582
[TBL] [Abstract][Full Text] [Related]
4. VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death.
Liu CS; Kong B; Xia HH; Ellem KA; Wei MQ
J Gene Med; 2001; 3(2):145-52. PubMed ID: 11318113
[TBL] [Abstract][Full Text] [Related]
5. VP22 and cytosine deaminase fusion gene modified tissue-engineered neural stem cells for glioma therapy.
Jin G; Zhou Y; Chai Q; Zhu G; Xu F; Liu F
J Cancer Res Clin Oncol; 2013 Mar; 139(3):475-83. PubMed ID: 23180018
[TBL] [Abstract][Full Text] [Related]
6. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
[TBL] [Abstract][Full Text] [Related]
7. Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells.
Fang B; Xu B; Koch P; Roth JA
Gene Ther; 1998 Oct; 5(10):1420-4. PubMed ID: 9930348
[TBL] [Abstract][Full Text] [Related]
8. Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors.
Lai Z; Han I; Zirzow G; Brady RO; Reiser J
Proc Natl Acad Sci U S A; 2000 Oct; 97(21):11297-302. PubMed ID: 11027330
[TBL] [Abstract][Full Text] [Related]
9. VP22-mediated intercellular transport correlates with enhanced biological activity of MybEngrailed but not (HSV-I) thymidine kinase fusion proteins in primary vascular cells following non-viral transfection.
Sheridan PJ; Lawrie A; Crossman DC; Holt CM; Newman CM
J Gene Med; 2005 Mar; 7(3):375-85. PubMed ID: 15543525
[TBL] [Abstract][Full Text] [Related]
10. Intercellular trafficking of VP22, a herpes simplex virus type 1 tegument protein.
Bamdad T; Bell JC
Iran Biomed J; 2007 Jan; 11(1):53-7. PubMed ID: 18051705
[TBL] [Abstract][Full Text] [Related]
11. Evidence for intercellular trafficking of VP22 in living cells.
Lemken ML; Wolf C; Wybranietz WA; Schmidt U; Smirnow I; Bühring HJ; Mack AF; Lauer UM; Bitzer M
Mol Ther; 2007 Feb; 15(2):310-9. PubMed ID: 17235309
[TBL] [Abstract][Full Text] [Related]
12. Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo.
Zavaglia D; Lin EH; Guidetti M; Pluquet O; Hainaut P; Favrot MC; Coll JL
J Gene Med; 2005 Jul; 7(7):936-44. PubMed ID: 15754307
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex virus VP22 enhances adenovirus-mediated microdystrophin gene transfer to skeletal muscles in dystrophin-deficient (mdx) mice.
Xiong F; Xiao S; Peng F; Zheng H; Yu M; Ruan Y; Li W; Shang Y; Zhao C; Zhou W; Chen H; Chamberlain JS; Fang L; Zhang C
Hum Gene Ther; 2007 Jun; 18(6):490-501. PubMed ID: 17550336
[TBL] [Abstract][Full Text] [Related]
14. Enhanced effect of myocardial gene transfection by VP22-mediated intercellular protein transport.
Suzuki K; Murtuza B; Brand NJ; Varela-Carver A; Fukushima S; Yacoub MH
J Mol Cell Cardiol; 2004 Apr; 36(4):603-6. PubMed ID: 15081320
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus.
Wills KN; Atencio IA; Avanzini JB; Neuteboom S; Phelan A; Philopena J; Sutjipto S; Vaillancourt MT; Wen SF; Ralston RO; Johnson DE
J Virol; 2001 Sep; 75(18):8733-41. PubMed ID: 11507218
[TBL] [Abstract][Full Text] [Related]
16. Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.
Bolhassani A; Gholami E; Zahedifard F; Moradin N; Parsi P; Doustdari F; Seyed N; Papadopoulou B; Rafati S
Exp Parasitol; 2011 May; 128(1):9-17. PubMed ID: 21276444
[TBL] [Abstract][Full Text] [Related]
17. HSV-1 VP22 augments adenoviral gene transfer to CNS neurons in the retina and striatum in vivo.
Kretz A; Wybranietz WA; Hermening S; Lauer UM; Isenmann S
Mol Ther; 2003 May; 7(5 Pt 1):659-69. PubMed ID: 12718909
[TBL] [Abstract][Full Text] [Related]
18. VP22-mediated intercellular transport for suicide gene therapy under oxic and hypoxic conditions.
Greco O; Joiner MC; Doleh A; Scott SD
Gene Ther; 2005 Jun; 12(12):974-9. PubMed ID: 15729368
[TBL] [Abstract][Full Text] [Related]
19. Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins.
Rutjes SA; Bosma PJ; Rohn JL; Noteborn MH; Wesseling JG
J Mol Med (Berl); 2003 Sep; 81(9):558-65. PubMed ID: 12879152
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors.
Zender L; Köck R; Eckhard M; Frericks B; Gösling T; Gebhardt T; Drobek S; Galanski M; Kühnel F; Manns M; Kubicka S
Gastroenterology; 2002 Aug; 123(2):608-18. PubMed ID: 12145813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
